Dana, Reza
Farid, Marjan
Gupta, Preeya K.
Hamrah, Pedram
Karpecki, Paul
McCabe, Cathleen M.
Nijm, Lisa
Pepose, Jay S.
Pflugfelder, Stephen
Rapuano, Christopher J.
Saini, Arvind
Gibbs, Sarah N.
Broder, Michael S.
Article History
Received: 17 May 2021
Accepted: 27 August 2021
First Online: 8 September 2021
Declarations
:
: Not applicable. Our study did not involve human subjects as defined in 45 CFR part 46, thus institutional review board approval was not required.
: Not applicable.
: Authors report the following competing interests, as noted in the ICMJE forms submitted with the manuscript.RD: Reports personal fees from Dompé during the conduct of the study; personal fees from Kala Pharmaceuticals, Novartis, GSK, and Claris Biotherapeutics; grants from Allergan and the NIH; other from Kera Therapeutics; and personal fees and other from Aramis Biosciences, GelMEDIX, and Claris Biotherapeutics outside the submitted work.MF: Reports personal fees from Dompé during the conduct of the study; personal fees from Allergan, Bio-Tissue, CorneaGen, Dompé, EyePoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and ZEISS outside the submitted work.PKG: Reports personal fees from Dompé during the conduct of the study.PH: Reports personal fees from Dompé during the conduct of the study; grants and personal fees from Dompé and personal fees from Neuroptika outside the submitted work.PK: Reports personal fees from Dompé during the conduct of the study; personal fees from Allergan/AbbVie, Bausch + Lomb, Bio-Tissue, Cambium, Dompé, EyeGate Pharma, OASIS Medical, Regener-Eyes, Sun Pharma, Novartis, Surface Pharmaceuticals, and Vital Tears outside the submitted work.CMC: Reports personal fees from Dompé during the conduct of the study; personal fees from Alcon, Aerie Pharmaceuticals, Bausch + Lomb, Johnson & Johnson Vision, Allergan, Novartis, Sun Pharma, Ivantis, Glaukos, ZEISS, Omeros, Ocular Therapeutix, EyePoint Pharmaceuticals, Sight Sciences, Engage Technologies Group, Science Based Health, MST, Ora, Dompé, and Tarsus outside the submitted work.LN: Reports personal fees from Dompé during the conduct of the study; personal fees from Akorn, Allergan, Bruder Healthcare Company, EyePoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LarciScience, Novartis, Alcon Pharmaceuticals, Omeros Corporation, Sun Pharma, and ZEISS; other from MDNegotiation.com; and grants and personal fees from Ocular Therapeutix outside the submitted work.JSP: Reports personal fees from Dompé during the conduct of the study; personal fees from Allergan, Bausch + Lomb, BRIM Biotechnology, Johnson & Johnson Vision, Keeler, Mimetogen, Novartis, OcuNexus, Ocuphire Pharma, Okogen, Stuart Pharmaceuticals, Sun Pharma, Théa, TearLab, and Dompé; and grants and personal fees from AcuFocus and Kala Pharmaceuticals outside the submitted work.SP: Reports personal fees from Dompé during the conduct of the study; personal fees from Kala Pharmaceuticals and Novartis, and grants and personal fees from Dompé outside the submitted work.CJR: Reports personal fees from Dompé during the conduct of the study; personal fees from Glaukos, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Sun Ophthalmics, TearLab, and Bio-Tissue outside the submitted work.AS: Reports personal fees from Dompé during the conduct of the study.MSB, SNG: Are employees of the Partnership for Health Analytic Research (PHAR), LLC, which received an Independent Medical Education Grant from Dompé US, Inc. (Grant ID: 87) to conduct the research described in this manuscript.